Inovio Pharmaceuticals has received a US patent covering SynCon vaccine for cervical dysplasias and cancers caused by human papillomavirus (HPV).
The patent covers Inovio's synthetic consensus HPV antigens, DNA constructs and vaccines that include these antigens, including VGX-3100, cervical dysplasia/cancer vaccine.
The methods used for treating patients with the SynCon cervical dysplasia/cancer vaccine were also protected.
Inovio president and CEO Joseph Kim said, "Because there is neither a therapeutic live virus vaccine nor non-replicating vaccine available for cervical dysplasias and cancers, Inovio's synthetic vaccine for these diseases answers an unmet need by providing a non-invasive and potentially more effective approach for treating women with this condition."
Under the existing license agreement with the Trustees of The University of Pennsylvania, the patent granted was exclusively licensed to Inovio.
